Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less ... more

• Transcriptional Misregulation in Cancer Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  There are today 204 companies plus partners developing 252 transcriptional misregulation targeting drugs in 965 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated...

• HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  Cancer cells are characterized by rapid proliferation and require adaptive metabolic responses to allow continued biosynthesis and cell growth in the setting of decreased oxygen (O(2)) and nutrient...

• Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the...

• Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update 2013

  EURO€ 999.00USD$ 1,300.00GBP£ 840.00AUD$ 1,271.00JPY¥ 128,320.00SEK 8 533,00CHF 1'225.00CAD$ 1,324.00 Bioseeker, Apr 2013
  Cell adhesion molecules are (glyco)proteins expressed on the cell surface and play a critical role in a wide array of biologic processes that include hemostasis, the immune response, inflammation, embryogenesis,...

• Adherens Junction Targeting in Oncology Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  Cell-cell adherens junctions, the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. There...

• Targeting Natural Killer Cell Mediated Cytotoxicity in Cancer Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  Natural killer (NK) cells are lymphocytes of the innate immune system that are involved in early defenses against both allogeneic (nonself) cells and autologous cells undergoing various forms of stress,...

• RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2013

  EURO€ 499.00USD$ 649.00GBP£ 420.00AUD$ 635.00JPY¥ 64,096.00SEK 4 262,00CHF 612.00CAD$ 662.00 Bioseeker, Apr 2013
  Specific families of pattern recognition receptors are responsible for detecting viral pathogens and generating innate immune responses. Non-self RNA appearing in a cell as a result of intracellular...

• Leptin Signaling Pathway in Oncology Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  The binding of Leptin to its receptor, LEPR induces various signaling modules such as JAK/STAT, RAS/RAF/MAPK, IRS/PI-3K and AMPK/ACC. There are today 246 companies plus partners developing 340 Leptin...

• Calcium Signaling Pathway in Cancer Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  There are today 155 companies plus partners developing 187 calcium signaling pathway targeting drugs in 724 developmental projects in cancer. In addition, the accumulated number of ceased drugs over...

• EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  The EGFR1 signaling pathway activates the Ras/Raf/MAPK signaling modules. There are today 351 companies plus partners developing 554 EGFR1 pathway targeting drugs in 1998 developmental projects in...

• FSH Signaling Pathway in Oncology Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  Follicle stimulating hormone (FSH) binds to FSH-receptor which is coupled to Gs protein that in turn activates cAMP dependent protein kinases (PKA) and thus triggers FSH signaling which continues further...

• RANKL Signaling Pathway in Oncology Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  Receptor activator of nuclear factor-kappa B ligand (RANKL) is a member of tumor necrosis factor (TNF) superfamily. It binds to Receptor activator of NF-kB (RANK) and plays a major role in the regulation...

• TSLP Signaling Pathway in Oncology Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine that play various roles in a broad spectrum of biological procedures. TSLP can be secreted by epithelial cells upon pathogen stimulation....

• Cell Cycle Targeting in Cancer Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  There are today 136 companies plus partners developing 144 targeting the cell cycle drugs in 463 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number...

• Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  Fc epsilon RI-mediated signaling pathways in mast cells are initiated by the interaction of antigen (Ag) with IgE bound to the extracellular domain of the alpha chain of Fc epsilon RI. The activation...

• TSH Signaling Pathway in Oncology Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  Human thyroid stimulating hormone (TSH) exerts its action through various signaling cascades such as cAMP cascade and the phospholipase C beta-mediated inositol phosphate generation. Further, it will...

• RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2013

  EURO€ 999.00USD$ 1,300.00GBP£ 840.00AUD$ 1,271.00JPY¥ 128,320.00SEK 8 533,00CHF 1'225.00CAD$ 1,324.00 Bioseeker, Apr 2013
  Potentially any disease-causing gene, cell type or tissue can be targeted with miRNA, RNAi or siRNA, including those not ’druggable’ with small molecules or protein-based therapies. There are today...

• Analytical Tool - Cancer Therapeutic Antibodies

  EURO€ 3,949.00USD$ 5,138.00GBP£ 3,322.00AUD$ 5,025.00JPY¥ 507,244.00SEK 33 732,00CHF 4'842.00CAD$ 5,235.00 Bioseeker, Apr 2013
  "Analytical Tool - Cancer Therapeutic Antibodies" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody drug development for the treatment of cancer....

• Thymus Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 37
  Thymus Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Thymus Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Uterine Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 308
  Uterine Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Uterine Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Neuroendocrine Tumors - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 79
  Neuroendocrine Tumors – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Neuroendocrine Tumors - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 47
  B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Burkitt Lymphoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 36
  Burkitt Lymphoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Burkitt Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Waldenstrom Macroglobulinemia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 109
  Waldenstrom Macroglobulinemia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Waldenstrom Macroglobulinemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 138
  Cutaneous T-Cell Lymphoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Indolent Lymphoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 100
  Indolent Lymphoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Indolent Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Osteosarcoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 74
  Osteosarcoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Osteosarcoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Metastatic Lung Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 38
  'Metastatic Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Metastatic Lung...

• EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022

  EURO€ 3,071.00USD$ 3,995.00GBP£ 2,584.00AUD$ 3,907.00JPY¥ 394,438.00SEK 26 231,00CHF 3'765.00CAD$ 4,071.00 GlobalData, Apr 2013 , Pages: 43
  EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022 Chronic Myeloid Leukemia (CML) is a rare cancer of the white blood cells characterized by increased and unregulated growth of...

• Breast Cancer - Pipeline Review, H1 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 Global Markets Direct, Apr 2013 , Pages: 524
  Breast Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Breast Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• T-Cell Lymphomas - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 222
  T-Cell Lymphomas – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'T-Cell Lymphomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Sarcomas - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 292
  Sarcomas – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Sarcomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 69
  Bile Duct Cancer (Cholangiocarcinoma) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Ovarian Cancer - Pipeline Review, H1 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 Global Markets Direct, Apr 2013 , Pages: 329
  Ovarian Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Ovarian Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Squamous Cell Carcinoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 213
  Squamous Cell Carcinoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Squamous Cell Carcinoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 492
  Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Lung Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 544
  Lung Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Glioma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 568
  Glioma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Glioma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Global Prostate Cancer Pipeline Capsule - 2013

  EURO€ 615.00USD$ 800.00GBP£ 517.00AUD$ 782.00JPY¥ 78,986.00SEK 5 253,00CHF 754.00CAD$ 815.00 Commercial Insights, Apr 2013 , Pages: 25
  Fore Pharma’s latest report ‘Global Prostate Cancer Pipeline Capsule – 2013’ provides up-to-date information on key Research and Development (R&D) activities in the global prostate cancer market. It...

• Global Gastric cancer Pipeline Capsule - 2013

  EURO€ 530.00USD$ 690.00GBP£ 446.00AUD$ 675.00JPY¥ 68,126.00SEK 4 530,00CHF 650.00CAD$ 703.00 Commercial Insights, Apr 2013 , Pages: 25
  Fore Pharma’s latest report ‘Global Gastric cancer Pipeline Capsule – 2013’ provides up-to-date information on key Research and Development (R&D) activities in the global gastric cancer market. It covers...

• Global Bladder Cancer Pipeline Capsule - 2013

  EURO€ 530.00USD$ 690.00GBP£ 446.00AUD$ 675.00JPY¥ 68,126.00SEK 4 530,00CHF 650.00CAD$ 703.00 Commercial Insights, Apr 2013 , Pages: 25
  Fore Pharma’s latest report ‘Global Bladder Cancer Pipeline Capsule – 2013’ provides up-to-date information on key Research and Development (R&D) activities in the global bladder cancer market. It covers...

• Global Ovarian Cancer Pipeline Capsule - 2013

  EURO€ 530.00USD$ 690.00GBP£ 446.00AUD$ 675.00JPY¥ 68,126.00SEK 4 530,00CHF 650.00CAD$ 703.00 Commercial Insights, Apr 2013 , Pages: 25
  Fore Pharma’s latest report ‘Global Ovarian Cancer Pipeline Capsule – 2013’ provides up-to-date information on key Research and Development (R&D) activities in the global ovarian cancer market. It covers...

• Global Head and Neck Cancer Pipeline Capsule - 2013

  EURO€ 530.00USD$ 690.00GBP£ 446.00AUD$ 675.00JPY¥ 68,126.00SEK 4 530,00CHF 650.00CAD$ 703.00 Commercial Insights, Apr 2013 , Pages: 25
  Fore Pharma’s latest report ‘Global Head and Neck Cancer Pipeline Capsule – 2013’ provides up-to-date information on key Research and Development (R&D) activities in the global head and neck cancer...

• Global Cervical Cancer Pipeline Capsule - 2013

  EURO€ 530.00USD$ 690.00GBP£ 446.00AUD$ 675.00JPY¥ 68,126.00SEK 4 530,00CHF 650.00CAD$ 703.00 Commercial Insights, Apr 2013 , Pages: 25
  Fore Pharma’s latest report ‘Global Cervical Cancer Pipeline Capsule – 2013’ provides up-to-date information on key Research and Development (R&D) activities in the global cervical cancer market. It...

• Global Colorectal Cancer Pipeline Capsule - 2013

  EURO€ 530.00USD$ 690.00GBP£ 446.00AUD$ 675.00JPY¥ 68,126.00SEK 4 530,00CHF 650.00CAD$ 703.00 Commercial Insights, Apr 2013 , Pages: 25
  Fore Pharma’s latest report ‘Global Colorectal Cancer Pipeline Capsule – 2013’ provides up-to-date information on key Research and Development (R&D) activities in the global colorectal cancer market....

• Global Breast Cancer Pipeline Capsule - 2013

  EURO€ 615.00USD$ 800.00GBP£ 517.00AUD$ 782.00JPY¥ 78,986.00SEK 5 253,00CHF 754.00CAD$ 815.00 Commercial Insights, Apr 2013 , Pages: 25
  Fore Pharma’s latest report ‘Global Breast Cancer Pipeline Capsule – 2013’ provides up-to-date information on key Research and Development (R&D) activities in the global breast cancer market. It covers...

• Global Lung Cancer Pipeline Capsule - 2013

  EURO€ 530.00USD$ 690.00GBP£ 446.00AUD$ 675.00JPY¥ 68,126.00SEK 4 530,00CHF 650.00CAD$ 703.00 Fore Pharma, Apr 2013 , Pages: 25
  Fore Pharma's latest report ‘Global Lung Cancer Pipeline Capsule – 2013' provides up-to-date information on key Research and Development (R&D) activities in the global lung cancer market It covers active...

• Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GBI Research, Apr 2013 , Pages: 88
  GBI Research, the leading business intelligence provider, has released its latest research, ""Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars...

• Molecular Diagnostics in Cancer Testing

  EURO€ 2,613.00USD$ 3,400.00GBP£ 2,199.00AUD$ 3,325.00JPY¥ 335,692.00SEK 22 324,00CHF 3'205.00CAD$ 3,465.00 TriMark Publications, Apr 2013 , Pages: 240
  Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added The technologies that come under the umbrella of molecular...

• Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GBI Research, Mar 2013 , Pages: 115
  GBI Research, the leading business intelligence provider, has released its latest research “Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival,...